Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(2):146-166.
doi: 10.2174/0115665240334785240913071442.

Stem Cells as a Novel Source for Regenerative Medicinal Applications in Alzheimer's Disease: An Update

Affiliations
Review

Stem Cells as a Novel Source for Regenerative Medicinal Applications in Alzheimer's Disease: An Update

Kratika Pandey et al. Curr Mol Med. 2025.

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by loss of the neurons, excessive accumulation of misfolded Aβ and Tau proteins, and degeneration of neural synapses, primarily occurring in the neocortex and the hippocampus regions of the brain. AD Progression is marked by cognitive deterioration, memory decline, disorientation, and loss of problem-solving skills, as well as language. Due to limited comprehension of the factors contributing to AD and its severity due to neuronal loss, even today, the medications approved by the U.S. Food and Drug Administration (FDA) are not precisely efficient and curative. Stem cells possess great potential in aiding AD due to their self-renewal, proliferation, and differentiation properties. Stem cell therapy can aid by replacing the lost neurons, enhancing neurogenesis, and providing an enriched environment to the pre-existing neural cells. Stem cell therapy has provided us with promising results in regard to the animal AD models, and even pre-clinical studies have shown rather positive results. Cell replacement therapies are potential curative means to treat AD, and there are a number of undergoing human clinical trials to make Stem Cell therapy accessible for AD patients. In this review, we aim to discuss the AD pathophysiology and varied stem cell types and their application.

Keywords: Alzheimer’s disease; clinical trial; dementia; neurodegenerative disease.; pathogenesis; stem cells.

PubMed Disclaimer

Similar articles

References

    1. Alzheimer’s Association. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement 2023,19(4),1598-1695 - DOI - PubMed
    1. Yiannopoulou K.G.; Papageorgiou S.G.; Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 2013,6(1),19-33 - DOI - PubMed
    1. Hameed S.; Fuh J.L.; Senanarong V.; Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer’s disease. J Alzheimers Dis Rep 2020,4(1),21-37 - DOI - PubMed
    1. Grossberg G.T.; Cholinesterase inhibitors for the treatment of Alzheimer’s disease: Getting on and staying on. Curr Ther Res Clin Exp 2003,64(4),216-235 - DOI - PubMed
    1. Lukiw W.J.; Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert Opin Emerg Drugs 2012,17(1),43-60 - DOI - PubMed

LinkOut - more resources